Evidence map›Paper›PMID 30241990›Full record

Trial reportSchizophrenia research2019

A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.

Delbert G Robinson, Juan A Gallego, Majnu John, Lauren A Hanna, Jian-Ping Zhang, Michael L Birnbaum, Jessica Greenberg, Melissa Naraine, Bart D Peters, Robert K McNamara and 2 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01786239 (Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment), which is not on this map. Cited by 38 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 8 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01786239 nacompletednot on this map

Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment

TypeinterventionalSponsorDelbert RobinsonRan2013 to 2015Enrolled50ConditionsSchizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar DisorderArmsRisperidone, Omega-3 capsules, Placebo
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 8 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Delbert G RobinsonDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA. Electronic address: drobinso@northwell.edu.
Juan A GallegoDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Majnu JohnThe Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA; Hofstra University, Hempstead, NY, USA.
Lauren A HannaThe Zucker Hillside Hospital, Glen Oaks, NY, USA.
Jian-Ping ZhangDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Michael L BirnbaumDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Jessica GreenbergThe Zucker Hillside Hospital, Glen Oaks, NY, USA.
Melissa NaraineThe Zucker Hillside Hospital, Glen Oaks, NY, USA.
Bart D PetersThe Zucker Hillside Hospital, Glen Oaks, NY, USA.
Robert K McNamaraUniversity of Cincinnati College of Medicine, Cincinnati, OH, USA.
Anil K MalhotraDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Philip R SzeszkoDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hemstead, NY, USA; The Feinstein Institute for Medical Research, Manhasset, NY, USA; The Zucker Hillside Hospital, Glen Oaks, NY, USA.
Zucker Hillside Hospital · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USFeinstein Institute for Medical Research · USHofstra University · USUniversity of Cincinnati Medical Center · US

Funding

Risk and protective factors for SGA-induced metabolic syndrome in bipolar youthR01DK097599 · NIDDK · UNIVERSITY OF CINCINNATI · PI MCNAMARA, ROBERT K. · 2013 to 2017
$1.7M
Detecting Which Patients With Schizophrenia Will Improve With Omega 3 TreatmentR21MH101746 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI ROBINSON, DELBERT G, SZESZKO, PHILIP R · 2013 to 2014
$463k
NIDDK NIH HHS R01 DK097599NIMH NIH HHS R21 MH101746
6 · The paper itself

Abstract

Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15-40 years with recent onset schizophrenia-spectrum (n = 46) or bipolar (n = 4) disorders and current psychotic symptoms were treated for 16 weeks with risperidone and randomly-assigned omega-3 (EPA 740 mg and DHA 400 mg daily) or matching placebo. The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) total score. Mean lifetime antipsychotic exposure was 18.1 days. Length of time in treatment, risperidone dose and number of omega-3/placebo capsules taken did not differ between conditions. Longitudinal analysis of the total BPRS score revealed a trend level (p = 0.0826) treatment effect favoring omega-3 treatment. Lorazepam was an allowed concomitant medication. Among the subgroup (N = 23) who did not receive lorazepam, the treatment effect on BPRS total scores favoring omega-3 was significant (p = 0.0406) and factor scores analyses revealed a substantial decrease in depression-anxiety with omega-3 but no change with placebo (treatment-by-time interaction, p = 0.0184). Motor side effects did not differ between conditions. Analysis of Systematic Assessment for Treatment Emergent Events assessments revealed fewer adverse events overall with omega-3 compared with placebo with the largest differences between conditions (all favoring omega-3) on confusion, anxiety, depression, irritability, and tiredness/fatigue. These results suggest that omega-3 adjuvant treatment is a potential option for depression and anxiety symptoms of people with recent onset psychosis. Further research is needed to confirm this potential. Clinical trial registration: NCT01786239.

Indexed as

AdolescentAdultAntipsychotic AgentsAnxietyBipolar DisorderBrief Psychiatric Rating ScaleDepressionDrug Therapy, CombinationFatty Acids, Omega-3FemaleHumansMaleOutcome Assessment, Health CarePsychotic DisordersRisperidoneSchizophreniaAntipsychotic AgentsFatty Acids, Omega-3RisperidoneAdjuvant treatmentAnxietyDepressionOmega-3Recent onset psychosisRisperidone

Identifiers

PMID30241990
PMCPMC6402999
OpenAlexW2889742164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.